GNGuillermo Servera Negre

Guillermo Servera Negre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guillermo Servera Negre has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

    by Rafaela de Moraes‐Souza, Maria Júlia Pilau Bornia, Regina Chahine Chater, Francesco Piscazzi, Matheus Barros de Albuquerque, Yasmin Mesquita, Izadora Lapenda, Guillermo Servera‐Negre, Natalia Hernández‐Cano, Rubiana Sarto, et al.

    Chronic hand eczema (CHE) is associated with substantial functional impairment and reduced quality of life. Delgocitinib, a pan‐Janus kinase (JAK) inhibitor, has emerged as a promising topical treatment for CHE. A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical delgocitinib 20–30 mg/g compared with vehicle in patients with CHE. PubMed, Embase, Cochrane Library, ClinicalTrials.gov , EU CTR, and WHO ICTRP were searched up to 15 February 2026. The primary outcome was treatment success at week 16, defined as clear or almost clear skin with a ≥ 2‐point improvement on the Investigator's or Physician's Global Assessment (IGA/PGA). Secondary outcomes included treatment success at weeks 4 and 8, changes in Hand Eczema Symptom Diary (HESD) itch and pain scores, and safety outcomes. Relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Three publications reporting four RCTs involving 1154 patients were included, with 752 receiving delgocitinib and 402 receiving vehicle. At week 16, treatment success was significantly higher with delgocitinib (RR 3.17; 95% CI 1.78–5.65; p < 0.01), corresponding to an absolute risk difference of 16.9% and a number needed to treat (NNT) of 6 (95% CI 3–16). Similar results at weeks 4 and 8. Delgocitinib also led to significantly greater improvements in HESD itch and pain scores. No significant differences were found in overall adverse events (AEs), treatment‐related AEs, or serious AEs. Discontinuation due to AEs was lower in the delgocitinib group. Delgocitinib 20–30 mg/g demonstrated greater efficacy than vehicle and a favourable safety profile, supporting its use as a topical treatment for CHE.


  • Open Access

    IL-15/IL-15Rα in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin

    by Teresa Bellón, Olga González-Valle, Elena Sendagorta, Victoria Lerma, Javier Martínez del Río, Celia Martínez, Guillermo Servera, Carlos González-Herrada, Lucía Cachafeiro, José A. Lorente, et al.

    Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening hypersensitivity reaction to medications characterized by keratinocyte apoptosis and skin detachment. IL-15 serum levels have been associated with severity and prognosis of SJS/TEN. We have measured IL-15 concentrations in serum and blister fluid (BF) from patients with SJS/TEN by ELISA and used quantitative RT-PCR to analyze the expression of IL15 and IL15RA (encoding for IL-15 Receptor-α chain) genes in peripheral blood and BF cells, including isolated monocytes, and in affected skin. A positive correlation was found between IL-15 serum levels and a percent of detached skin. BF concentrations were higher, but no correlation was found. Higher IL15 and IL15RA gene expression levels were found in skin-infiltrating blister fluid cells compared to peripheral mononuclear cells. Moreover, IL15RA transcripts were barely detected in healthy skin, being the highest expression levels found in samples from two SJS/TEN patients who did not survive. The cutaneous expression of IL-15Rα in SJS/TEN may provide an explanation to the tissue-specific immune cytotoxic response in this clinical entity, and the results suggest that the effects of IL-15 in SJS/TEN patients may be dependent on the expression of its private receptor IL-15Rα in affected skin.


  • Response of Darier Disease Following Treatment With Baricitinib

    by José Manuel Busto Leis, Guillermo Servera Negre, Ander Paulo Mayor Ibarguren, Pedro Herranz Pinto

    This case report describes a middle-aged woman with a long-standing papular eruption that affected the scalp, chest, forearms, and skin folds.


  • Development of Machine Learning–Based Predictor Algorithm for Conversion of an Ommaya Reservoir to a Permanent Cerebrospinal Fluid Shunt in Preterm Posthemorrhagic Hydrocephalus

    by Miguel Sáez-Alegre, Rocío Martín, Alexis Palpán, Fernando Carceller, Jesús Sáez-Alegre, Guillermo Servera, Rudolf Bauer, Pablo García Feijoo, Javier Saceda


  • Open Access

    Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance

    by J.M. Busto‐Leis, G. Servera‐Negre, A. Mayor‐Ibarguren, E. Sendagorta‐Cudós, M. Feito‐Rodríguez, A. Nuño‐González, Montero‐ Vega, P. Herranz‐Pinto